Showing 1 - 20 results of 49 for search 'N. Barnes', query time: 0.09s
Refine Results
-
1
-
2
The effects of heterogeneity on Simon Phase II clinical trial design operating characteristics by Christopher N Barnes, Shesh N Rai
Published 2010-07-01
Article -
3
Habitual exercise in youth: A ʻbrainyʼ idea by Jill N. Barnes, Tracy Baynard, Patrice Brassard
Published 2023-12-01
Article -
4
-
5
-
6
A Systematic Review of Zoonotic Enteric Parasites Carried by Flies, Cockroaches, and Dung Beetles by Avi Patel, Meg Jenkins, Kelly Rhoden, Amber N. Barnes
Published 2022-01-01
Article -
7
-
8
Causes and consequences of sympathoexcitation across the lifespan: Physiological or pathological? by Zoe H. Adams, Jill N. Barnes, Rachel N. Lord
Published 2023-10-01
Article -
9
-
10
-
11
Twenty years of waterborne and related disease reports in Florida, USA by Kelly Rhoden, Jose Alonso, Meg Carmona, Michelle Pham, Amber N. Barnes
Published 2021-12-01
Article -
12
-
13
-
14
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III tri... by Sanjay Sethi, James F. Donohue, Gary T. Ferguson, Chris N. Barnes, Glenn D. Crater
Published 2020-02-01
Article -
15
Comparison of augmentation index derived from multiple devices by Mandeep Dhindsa, Jill N. Barnes, Allison E. DeVan, Jun Sugawara, Hirofumi Tanaka
Published 2011-07-01
Article -
16
-
17
-
18
Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials by Michael S. Niederman, Patrick C. Lee, Steven L. Barriere, Chris N. Barnes, Bibiana Castaneda-Ruiz
Published 2019-08-01
Article -
19
-
20
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis by James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Glenn D. Crater
Published 2020-05-01
Article